Clinical trials: Surrogate endpoints or hard endpoints?

American Journal of Cardiology

Volumn 88, Issue 2 SUPPL. 1, 2001, Pages 59-61

  Kuller, Lewis H ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; FIBRINOLYSIS; HEART INFARCTION; HEART INFARCTION PREVENTION; HIGH RISK POPULATION; HOST SUSCEPTIBILITY; HUMAN; INFLAMMATION; LIFESTYLE; LIPOPROTEIN METABOLISM; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; THROMBOSIS;

EID: 0035913136     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01786-6     Document Type: Article

References (27)

1. The importance of preclinical disease: Lessons from the Cardiovascular Health Study
2. The epidemiology of atherosclerosis in 1987: Unraveling a common-source epidemic
3. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease
4. Natural history of ischemic heart disease in relation to arteriographic findings: A twelve year study of 224 patients
5. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography
6. Prediction of coronary events with electron beam computed tomography
7. Coronary calcification by electron beam computed tomography and obstructive coronary artery disease: A model for costs and effectiveness of diagnosis as compared with conventional cardiac testing methods
8. Atherosclerosis
9. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?
10. The role of inflammation in cardiovascular disease
11. Inflammation markers and coronary heart disease
12. Novel inflammatory markers of coronary risk: Theory versus practice
13. Prevention Conference V. Beyond secondary prevention: Identifying the high-risk patient for primary prevention. Noninvasive tests of atherosclerotic burden
14. Guide to primary prevention of cardiovascular diseases: A statement for healthcare professionals from the Task Force on Risk Reduction
15. At what level of coronary heart disease risk should a statin be prescribed?
16. Risk factors for coronary and cerebral atherosclerosis in the Oslo study
17. Influence of serum cholesterol, blood pressure, and cigarette smoking on death from coronary heart disease in 316,099 white men age 35-57 years: Overall findings and differences by age
18. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: Findings for 5 large cohorts of young adult and middle-aged men and women
19. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: The Healthy Women Study
20. Aging and cardiovascular disease: Use of subclinical measurements
21. Are hostility and anxiety associated with carotid atherosclerosis in healthy postmenopausal women?
22. High levels of Lp(a) isoform are associated with coronary artery disease in African American and white men
23. Novel risk factors for atherosclerosis
24. Diabetes mellitus: Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality
25. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
26. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study
27. Coronary artery calcification in older adults with minimal clinical or subclinical cardiovascular disease